Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and outcomes for UBM or TCD transplants

	UBM	TCD	P
Patient and transplant characteristics
No. patients	37	40
Mean age, y, (range) at transplantation	37 (11-54)	35 (13-52)	.62
Men, %	68	58	.19
Mean Karnofsky performance status score at conditioning	91	91	.55
KIR mismatch with donor, %	11	13	.83
6/6 HLA match with donor, %	76	58	.01
Cyclosporin acute GVHD prophylaxis, %	81	70	.10
Date of transplantation, median (range)	Apr 1995 (1990-1999)	Nov 1995 (1990-1999)	.70
Mean time from diagnosis to transplantation, mo	25	27	.66
Transplantation at first chronic phase, %	73	63	.13
Preparative regimen			.49
Cytoxan and total body irradiation, %	78	85
Cytoxan and busulfan, %	14	10
Other, %	8	5
Treatments and outcomes
Acute GVHD any, %	78	68	.15
Acute GVHD grade II–IV, %	73	45	< .001
Systemic steroids for acute GVHD treatment, %	70	65	.55
Chronic GVHD, %	65	45	.007
Relapse, %	19	30	.10
5-y survival, %	54	52	.89

	UBM	TCD	P
Patient and transplant characteristics
No. patients	37	40
Mean age, y, (range) at transplantation	37 (11-54)	35 (13-52)	.62
Men, %	68	58	.19
Mean Karnofsky performance status score at conditioning	91	91	.55
KIR mismatch with donor, %	11	13	.83
6/6 HLA match with donor, %	76	58	.01
Cyclosporin acute GVHD prophylaxis, %	81	70	.10
Date of transplantation, median (range)	Apr 1995 (1990-1999)	Nov 1995 (1990-1999)	.70
Mean time from diagnosis to transplantation, mo	25	27	.66
Transplantation at first chronic phase, %	73	63	.13
Preparative regimen			.49
Cytoxan and total body irradiation, %	78	85
Cytoxan and busulfan, %	14	10
Other, %	8	5
Treatments and outcomes
Acute GVHD any, %	78	68	.15
Acute GVHD grade II–IV, %	73	45	< .001
Systemic steroids for acute GVHD treatment, %	70	65	.55
Chronic GVHD, %	65	45	.007
Relapse, %	19	30	.10
5-y survival, %	54	52	.89